Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11021220 | 0.76 | HSD11B1 (0.46) | HTTALDH1A1KDM4EGLAGAA | |
| SCHEMBL296497 | 0.75 | KDM4E (0.45) | LMNAMCL1ALDH1A1KDM4EGLA | |
| SCHEMBL11027019 | 0.74 | CA2 (0.47) | MAPTCYP2C9HTTALDH1A1KDM4E | |
| SCHEMBL1162742 | 0.74 | PIM1 (0.54) | MAPTALDH1A1KDM4EPIM1GLA | |
| SCHEMBL7064467 | 0.73 | MAPT (0.53) | MAPTLMNACYP2C9HTTALDH1A1 | |
| SCHEMBL31124656 | 0.73 | MAPT (0.53) | MAPTLMNACYP2C9HTTALDH1A1 | |
| SCHEMBL18257252 | 0.72 | PDE3B (0.40) | MAPTMCL1HTTALDH1A1KDM4E | |
| SCHEMBL8165980 | 0.72 | MAPT (0.46) | MAPTLMNAMCL1ALDH1A1KDM4E | |
| SCHEMBL25210536 | 0.71 | PRKCQ (0.39) | MAPTLMNACYP2C9ALDH1A1KDM4E | |
| SCHEMBL10340373 | 0.71 | MTNR1A (0.43) | MAPTLMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115504904-A | Gelmethine intermediate compound and preparation method thereof | 山东新时代药业有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-115504906-A | Gelmethylpyrimidine intermediate compound | 山东新时代药业有限公司 | 2022-12-23 | — | — | CN | claimed |
| US-20250084395-A1 | ENGINEERED NITRILASES FOR BIOCATALYSIS | KCAT ENZYMATIC PRIVATE LIMITED (IN) | 2025-03-13 | — | — | US | disclosed |
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-116648244-B | Terpyridyl dione compound or salt thereof, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116648244-A | Terpyridyl dione compound or salt thereof, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4219463-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219463-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023016535-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-0946550-B1 | PREPARATION OF [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-CHLORO-2-THIENYL)METHYL]PROPYL]AMINO]-3H-IMIDAZO[4,5-b]PYRIDIN-3-yl]-N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE | AVENTIS PHARMA INC (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| EP-0946550-A4 | PREPARATION OF 1S- 1a,2b,3b,4a(S*)]]-4- 7- 1-(3-CHLORO-2-THIENYL) METHYL]PROPYL]AMINO]-3H-IMIDAZO 4,5-b]PYRIDIN-3-yl]-N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE | AVENTIS PHARM PROD INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6235909-B1 | HYDROLYZING AND DECARBOXYLATING 2-HYDROXY-3-CYANO-4-METHOXY PYRIDINE TO GIVE 2,4-DIHYDROXYPYRIDINE, FOLLOWED BY NITRATION TO PREPARE 4-HYDROXY-3-NITRO-2(1H)-PYRIDONE | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-05-22 | — | — | US | disclosed |
| US-6143894-A | Preparation of [1S-[1A,2B,3B,4A(S*)]]-4-[7-[[1-(3-chloro-2-thienyl)methyl propyl]amino] -3H-imidazo[4,5-B]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentanecarboxa mide | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0946550-A1 | PREPARATION OF 1S- 1a,2b,3b,4a(S*)]]-4- 7- 1-(3-CHLORO-2-THIENYL) METHYL]PROPYL]AMINO]-3H-IMIDAZO 4,5-b]PYRIDIN-3-yl]-N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998025921-A1 | PREPARATION OF [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-CHLORO-2-THIENYL) METHYL]PROPYL]AMINO]-3H-IMIDAZO[4,5-b]PYRIDIN-3-yl]-N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | TNF, MAPKAPK2, MAPK1 | MAPT 3206/4885LMNA 4712/4885CYP2C9 912/4885 |
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPT 2803/4885LMNA 1815/4885CYP2C9 1124/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPT 2543/4885LMNA 1884/4885CYP2C9 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.